 |
|
Lorenzo’s Oil: Advances in the Treatment of Neurometabolic Disorders
Arch Neurol. 2005;62:1045-1046.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Inherited neurometabolic disorders are individually rare and have many causes. Many are progressive disorders with treatment options limited to symptomatic care. X-linked adrenoleukodystrophy (ALD) is a rare disorder first described almost 100 years ago. As a result of intense basic science and clinical research, remarkable progress has been made in elucidating the biochemical irregularities, molecular genetics, diagnostic testing, and pathogenesis of this disorder. In recent years, extraordinary progress has also been made in developing effective treatments, and ALD serves as an excellent model for the treatment of neurometabolic diseases. It is a progressive disorder characterized by Addison disease, childhood dementia, and neurologic deterioration to a vegetative state. A key discovery was the identification of lipid inclusions consisting of cholesterol esters and an excess of very long-chain fatty acids (VLCFAs) in adrenal cells.1 This finding led to the development of specific assays for diagnosis, and it localized the subcellular irregularity to . . . [Full Text of this Article]AUTHOR INFORMATION
Raymond Ferri, MD, PhD;
Phillip F. Chance, MD
RELATED ARTICLE
Follow-up of 89 Asymptomatic Patients With Adrenoleukodystrophy Treated With Lorenzo’s Oil
Hugo W. Moser, Gerald V. Raymond, Shou-En Lu, Larry R. Muenz, Ann B. Moser, Jiahong Xu, Richard O. Jones, Daniel J. Loes, Elias R. Melhem, Prachi Dubey, Lena Bezman, N. Hong Brereton, and Augusto Odone
Arch Neurol. 2005;62(7):1073-1080.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Uptake and metabolism of plasma-derived erucic acid by rat brain
Golovko and Murphy
J. Lipid Res. 2006;47:1289-1297.
ABSTRACT
| FULL TEXT
|
